

## TITAN MEDICAL INC.

### INSIDER TRADING POLICY

#### POLICY STATEMENT

Securities and corporate laws in Canada and the United States prohibit directors, officers and employees and any person in a special relationship with Titan Medical Inc. (“Titan”) and any subsidiaries of Titan from buying or selling securities of Titan while having material information that has not yet been made public. These laws also prohibit such information from being passed on to others (including to a spouse, relative or friend). Also, certain directors and officers of Titan and its subsidiaries are subject to reporting obligations under Canadian securities laws (including the filing of insider reports on SEDI). Violation of these laws could result in prosecution and termination of Titan’s association with the offending person and could seriously affect Titan.

The purpose of this Insider Trading Policy (the “**Policy**”) is to safeguard against violations of such laws. This Policy is also intended to ensure that the directors, officers, employees and persons in a special relationship with Titan act, and are perceived to act, in accordance with applicable laws and the highest standards of ethical and business conduct.

This Policy and any revisions to it must be approved by the Corporate Governance and Nominating Committee.

#### APPLICATION

##### Persons Covered by the Policy

The restrictions on trading and informing others in Part A of this Policy apply to all directors, officers and employees of Titan or a subsidiary of Titan. The reporting rules in Part B of this Policy apply only to “Reporting Insiders”, which is defined below.

Each person to whom this Policy applies is individually responsible for complying with it (as well as the securities laws applicable to their region), regardless of whether Titan has prohibited trading by that person or any other persons.

#### Definitions

For the purposes of this Policy:

1. “**Acquisition Target**” means a public company or entity (i) of which Titan proposes to acquire outstanding shares or equity interests or a substantial portion of its assets or (ii) with which Titan proposes to enter into a reorganization, amalgamation, merger, arrangement or similar business combination.
2. “**Confidential Material Information**” means Material Information about Titan or another company or entity that has not been generally disclosed.
3. “**economic exposure**” in relation to a reporting issuer means the extent to which the economic or financial interests of a person or company are aligned with the trading price of securities of Titan or the economic or financial interests of Titan.
4. “**economic interest in a security**” means,
  - (a) a right to receive or the opportunity to participate in a reward, benefit or return from a security, or

- (b) an exposure to a loss or a risk of loss in respect of a security.
5. **“Material Information”** means information respecting a company or entity that, if disclosed, would reasonably be expected to have a significant effect on the market price or value of the company’s or entity’s securities. Material Information consists of both material facts and material changes relating to the activities of the company or entity and its subsidiaries, as well as their businesses and affairs. Examples of the types of events or information that may be material are set out in **Schedule A** to this Policy.
6. **“Related Financial Instrument”** means:
- (a) “related financial instrument” means an agreement, arrangement or understanding to which an insider of a reporting issuer is a party, the effect of which is to alter, directly or indirectly, the insider’s,
    - (i) economic interest in a security of Titan, or
    - (ii) economic exposure to Titan.
7. **“Reporting Insider”** means:
- (a) the chief executive officer, chief financial officer, or chief operating officer (if any) of the reporting issuer, of a Significant Shareholder of the reporting issuer or of a major subsidiary of the reporting issuer;
  - (b) a director of the reporting issuer, of a Significant Shareholder of the reporting issuer or of a major subsidiary of the reporting issuer;
  - (c) a person or company responsible for a principal business unit, division or function of the reporting issuer;
  - (d) a Significant Shareholder of the reporting issuer;
  - (e) a management company that provides significant management or administrative services to the reporting issuer or a major subsidiary of the reporting issuer, every director of the management company, every chief executive officer, chief financial officer, chief technology officer (if any) or chief operating officer (if any) of the management company, and every significant shareholder of the management company;
  - (f) an individual performing functions similar to the functions performed by any of the insiders described in paragraphs (a) to (e), which shall include the Senior Vice-President of Research and Development;
  - (g) the reporting issuer itself, if it has purchased, redeemed or otherwise acquired a security of its own issue, for so long as it continues to hold that security; or
  - (h) any other insider that:
    - (i) in the ordinary course receives or has access to information as to any material facts or material changes concerning the reporting issuer before the material facts or material changes are generally disclosed; and

- (ii) directly or indirectly exercises, or has the ability to exercise, significant power or influence over the business, operations, capital or development of the reporting issuer.
- 8. **“Significant Shareholder”** means a person or company that has beneficial ownership of, or control or direction over, whether direct or indirect, or a combination of beneficial ownership of, and control or direction over, whether direct or indirect, securities of Titan carrying more than 10 per cent of the voting rights attached to all Titan’s outstanding voting securities, excluding, for the purpose of the calculation of the percentage held, any securities held by the person or company as underwriter in the course of a distribution.

**PART A**  
**RESTRICTIONS ON TRADING AND INFORMING OTHERS**

**APPLICABLE TO ALL DIRECTORS, OFFICERS AND EMPLOYEES OF TITAN OR ITS  
SUBSIDIARIES (IF ANY)**

**Rules**

Under applicable securities laws, directors, officers and employees of Titan and its subsidiaries are in a “special relationship” with Titan and, as a result, are prohibited from purchasing or selling shares or other securities of Titan (including exercises of stock options where the underlying shares are sold) while in possession of Confidential Material Information. Passing on such information to a third party (known as “tipping”), other than in the necessary course of business, is also prohibited.

Accordingly, rules A1 and A2 provide as follows:

A1. **No trading while in possession of Confidential Material Information** – Anyone having knowledge of Confidential Material Information respecting:

- (a) Titan is prohibited from trading in Titan’s securities; or
- (b) any public company or entity, if it is an Acquisition Target or if the Confidential Material Information was obtained through Titan’s business discussions, is prohibited from trading in that public company’s or entity’s securities

until after the close of business on the second business day following the day the Material Information has been disclosed to the public. If in doubt, the cautious approach is not to trade. Directors, officers and employees are often in positions of perceived and actual trust – any trading by them, even if not technically illegal, can have a negative impact on the market and on corporate relations.

A2. **No tipping of Confidential Material Information to anyone** – Anyone having knowledge of Confidential Material Information respecting:

- (a) Titan; or
- (b) any public company or entity, if it is an Acquisition Target or if the Confidential Material Information was obtained through Titan’s business discussions,

is prohibited from informing anyone (including spouses, relatives and friends) of such Confidential Material Information, except in the necessary course of business, until after the close of business on the second business day following the day the Material Information has been disclosed to the public. Examples of the kinds of disclosure that may be considered to be in the necessary course of business are set out in **Schedule B** to this Policy.

For purposes of the above rule A2, “anyone” includes a spouse, children, parents, siblings and other relatives and friends. This restriction is necessary in order to protect Titan from inadvertent leaks of Confidential Material Information and to protect the disclosing individual, as well as such persons, from violating securities law. Both the TSX and NASDAQ use sophisticated electronic surveillance techniques to uncover insider trading.

A3. **No short-term speculative trading in Titan’s securities** – Frequent trading may create a perception that directors, officers or employees are using their access to information that

is not available to public investors to profit personally. Persons subject to rules A1 or A2 should not make frequent “in and out” trades (a buy following a sell or a sell following a buy) in the same or equivalent security within a short period of time. However, this rule does not apply to the sale of Titan’s securities shortly after they were acquired pursuant to the exercise of stock options granted under Titan’s stock option plan (the “Stock Option Plan”).

- A4. **No short sales of Titan’s securities** – The sale of Titan’s securities that are not owned or fully paid for at the time of sale is prohibited. However, this rule does not apply to directors, officers or employees where the sale occurs in connection with the exercise of a stock option granted under the Stock Option Plan and the number of securities acquired on such exercise equals or exceeds the number of securities sold.
- A5. **Prohibitions on “calls” and “puts” of Titan’s securities** – The sale of a “call” on Titan’s securities (i.e. giving someone else the right to buy Titan’s securities at a pre-established price on a later date) and the buying of a “put” on Titan’s securities (i.e. acquiring the right to sell securities of Titan to someone else at a pre-established price on a later date) is prohibited.
- A6. **Prohibition on holding Titan’s securities in margin accounts** – Securities held in a margin account with a broker may be sold without the account-holder’s consent in the event of a margin call. To avoid any risk that a margin call results in the sale of Titan’s securities at a time when an individual has knowledge of Confidential Material Information or is otherwise prohibited from trading, Titan’s securities may not be purchased on margin or held in a margin account with a broker.
- A7. **No fraudulent trading or market manipulation respecting Titan’s securities** – It is prohibited to directly or indirectly engage or participate in any act, transaction, trading method or other practice, or course of conduct, that an individual knows or ought reasonably to know (i) results in or contributes to a misleading appearance of trading activity in, or on an artificial price for, Titan’s securities; or (ii) perpetrates a fraud on any person or company.
- A8. **Blackout periods** – Trading is prohibited in the following regularly scheduled “blackout” periods:
  - (a) during the period commencing when the TSX and NASDAQ close on the day that is the 15<sup>th</sup> day after the last day of each quarter and ending on the close of business on the first business day following the day on which Titan publicly discloses the previous fiscal period’s financial results. If the 15<sup>th</sup> day after the last day of the quarter falls on a weekend or a TSX or NASDAQ holiday, the blackout period will start when the TSX and NASDAQ close on the last trading day prior to the weekend or TSX or NASDAQ holiday;
  - (b) after the receipt of a notice from the Corporate Secretary of Titan of an instruction not to trade until further notice is given.

Trading outside the above described blackout periods should not be considered a “safe harbour”.

### **General**

- 1. Employees, officers and directors are required to consult the CFO or a designate of the CFO, if they are unsure whether they may trade in a given circumstance. Any approval

granted for a proposed trade will be valid for a period of five (5) business days unless revoked prior to that time. Attached as **Schedule C** to this Policy is a suggested form of notification to be used in situations where an employee is unsure whether they may trade. Employees are reminded that, notwithstanding the approval of any such trade, the ultimate responsibility for complying with this Policy and applicable laws and regulations rests with the individual.

2. Individuals should not discuss investments in Titan with people outside of Titan other than in the necessary course of business.
3. Where Confidential Material Information is disclosed in the necessary course of business, care should be taken to ensure that the recipient understands and accepts their obligations under securities laws respecting prohibitions on trading or tipping while in possession of such Confidential Material Information. This can be done by having the recipient acknowledge that they will comply with securities laws respecting insider trading and by putting a provision to that effect in the confidentiality agreement that such recipient has entered into with Titan or a subsidiary of Titan.
4. Even if a director, officer or employee ceases to hold any position with Titan or a subsidiary of Titan, under Canadian and United States securities laws such an individual continues to be subject to the prohibitions in rules A1 and A2. Titan recommends that the person should consult with the Corporate Secretary if that person is unclear as to whether he or she remains in possession of Confidential Material Information.
5. Nothing contained in this Policy limits Titan's directors, officers, employees and others in possession of Confidential Material Information to file a charge or complaint with a governmental regulatory agency in the United States and nothing herein limits their ability to communicate with any such agencies or otherwise participate in any investigation or proceeding that may be conducted by any such agency, including providing documents or other information, without notice to Titan.

**PART B  
INSIDER REPORTING**

**APPLICABLE TO ALL REPORTING INSIDERS**

**Rules**

- B1. **Approvals for trades in Titan's securities and derivatives** – Reporting Insiders must not trade Titan's securities or acquire, dispose of, enter into, modify or terminate a Related Financial Instrument without the prior approval of the Chief Financial Officer or a designate of the Chief Financial Officer. The Chief Executive Officer, may not trade Titan securities or acquire, dispose of, enter into, modify or terminate a Related Financial Instrument without the prior approval of the Chief Financial Officer. The Chief Financial Officer may not trade Titan securities or acquire, dispose of, enter into, modify or terminate a Related Financial Instrument without the prior approval of the Chief Executive Officer. Any approval granted for a proposed trade will be valid for a period of five (5) business days unless revoked prior to that time. Attached as **Schedule C** to this Policy is a suggested form of notification to be used in connection with a proposed purchase, sale or other transaction in Titan's securities, as described above. Reporting Insiders are reminded that, notwithstanding the approval of any such trade, the ultimate responsibility for complying with this Policy and applicable laws and regulations rests with the individual.
- B2. **Filing of initial reports** – An individual who becomes a Reporting Insider must file an insider profile and an initial insider report within five calendar days of becoming a Reporting Insider. The Chief Financial Officer or his/her designate will attend to the filing of the insider profile and initial insider report if requested to do so by the Reporting Insider. Reporting Insiders who file their own reports are asked to promptly provide a copy of such reports to the Chief Financial Officer in order that Titan's records may be updated.
- B3. **Filing of subsequent reports** – Reporting Insiders must file:
- (a) an insider report to reflect any change in beneficial ownership of, or control or direction over, whether direct or indirect, Titan's securities or any change in an interest in, or right or obligation associated with, a Related Financial Instrument, within five calendar days of such change; and
  - (b) an amended insider profile to reflect any change in the information contained in the Reporting Insider's most recent insider profile, prior to filing their next insider report or, in the case of a change to the Reporting Insider's relationship to Titan, within five calendar days of such change.

**General**

The Chief Financial Officer (or his/her designate) will file insider reports on a Reporting Insider's behalf if requested to do so, and if prompt notification of the trade details are provided to his/her office. Reporting Insiders who file their own reports are asked to promptly provide a copy of such reports to the Chief Financial Officer in order that Titan's records may be updated.

**ENFORCEMENT OF POLICY**

Titan will remind directors, officers and employees of the provisions of this Policy and its importance not less than once annually (typically, in connection with a notice of the end of a blackout period). Violations of this Policy can be a violation of securities laws and may cause serious negative consequences to Titan. If Titan discovers a violation of securities laws, it may refer the matter to the appropriate regulatory authorities without notification to the person or

persons involved. In addition, disciplinary action may be brought against anyone who violates this Policy, which could result in termination of employment or position.

Under applicable securities laws, the penalties for illegal insider trading and tipping are severe and include:

- (a) per Canadian laws, a fine of up to three times the profit made or \$5,000,000 (whichever is greater), or imprisonment for up to five years less one day, or both;
- (b) in the United States, criminal penalties for violations of insider trading laws by individuals include possible imprisonment for a term of up to twenty years and fines of up to US\$5,000,000 or, for non-natural persons, US\$25,000,000;
- (c) civil liability for damages caused to the person to whom the securities were sold or from whom the securities were purchased;
- (d) civil liability for damages suffered by a person who sold securities to, or purchased securities from, someone who traded with knowledge of Confidential Material Information, learned, directly or indirectly, from the individual who disclosed the Confidential Material Information; or
- (e) an obligation to account to Titan for any benefit or advantage received or receivable in connection with the prohibited action.

Illegal insider tipping and trading is also prohibited under applicable criminal laws. Penalties under the Criminal Code include a term of imprisonment for up to ten years.

Late filing of insider reports gives rise to penalties in Ontario, Manitoba, British Columbia and Quebec. Fees for late filing of insider reports vary from jurisdiction to jurisdiction, and currently can be as high as \$100 for each calendar day that the insider report is late subject to a maximum of \$5,000 within any one year. Reporting Insiders are reminded that they remain personally responsible for the timely disclosure of their trading activities. Any assistance offered by the Chief Financial Officer in no way reduces the obligations imposed on them by applicable insider trading laws. Despite any such assistance that may be provided, Titan assumes no liability for any costs, claims or charges incurred as a result of any delay in filing of insider reports or any inaccuracies or incomplete information in the insider reports, whether or not such insider reports are prepared by Titan.

Questions regarding this Policy should be directed to Titan's Chief Financial Officer.

**Last reviewed and approved by the Board of Directors: December 2020**



## **SCHEDULE A**

### **INFORMATION THAT MAY BE MATERIAL**

The following are examples of the types of events or information that may be material. Most of these examples are taken from National Policy 51-201 – *Disclosure Standards*, which is a policy of each of the securities regulators in Canada. This list is not exhaustive and is not a substitute for parties exercising their own judgement in making materiality determinations.

#### **Changes in Corporate Structure**

- changes in share ownership that may affect control of the company
- major reorganizations, amalgamations, or mergers
- take-over bids, issuer bids, or insider bids

#### **Changes in Capital Structure**

- the public or private sale of additional securities
- planned repurchases or redemptions of securities
- planned splits of common shares or offerings of warrants or rights to buy shares
- any share consolidation, share exchange, or stock dividend
- changes in a company's dividend payments or policies
- the possible initiation of a proxy fight
- material modifications to rights of security holders

#### **Changes in Financial Results**

- a significant increase or decrease in near-term earnings prospects
- unexpected changes in the financial results for any periods
- shifts in financial circumstances, such as cash flow reductions, major asset write-offs or write-downs
- changes in the value or composition of the company's assets
- any material change in the company's accounting policy
- changes in any financial metric that would indicate a significant change in the Company's future prospects

#### **Changes in Business and Operations**

- any development that affects the company's resources, technology, products or markets
- a significant change in capital investment plans or corporate objectives
- major labour disputes or disputes with major contractors or suppliers
- significant new contracts, products, patents, or services or significant losses of contracts or business
- significant discoveries by resource companies

- changes to the board of directors or executive management, including the departure of the company's Chief Executive Officer, Chief Financial Officer, Chief Technology Officer, Chief Operations Officer or president (or persons in equivalent positions)
- the commencement of, or developments in, material legal proceedings or regulatory matters
- waivers of corporate ethics and conduct rules for officers, directors, and other key employees
- any notice that reliance on a prior audit is no longer permissible
- de-listing of the company's securities or their movement from one quotation system or exchange to another

#### **Acquisitions and Dispositions**

- significant acquisitions or dispositions of assets, property or joint venture interests
- acquisitions of other companies, including a take-over bid for, or merger with, another company

#### **Changes in Credit Arrangements**

- the borrowing or lending of a significant amount of money
- any mortgaging or encumbering of the company's assets
- defaults under debt obligations, agreements to restructure debt, or planned enforcement procedures by a bank or any other creditors
- changes in rating agency decisions
- significant new credit arrangements

## **SCHEDULE B**

### **NECESSARY COURSE OF BUSINESS**

The “necessary course of business” exception would generally cover communications with:

- (a) vendors, suppliers, or strategic partners on issues such as research and development, sales and marketing, and supply contracts;
- (b) employees, officers, and board members;
- (c) lenders, legal counsel, auditors, underwriters, and financial and other professional advisors to the company;
- (d) parties to negotiations;
- (e) labour unions and industry associations;
- (f) government agencies and non-governmental regulators; and
- (g) credit rating agencies (provided that the information is disclosed for the purpose of assisting the agency to formulate a credit rating and the agency’s ratings generally are or will be publicly available).

However, the “necessary course of business” exemption does not permit Titan to make selective disclosure of material information to analysts, institutional investors or other market professionals. Disclosure of material information to credit rating agencies is permitted if such disclosure is in the “necessary course of business”.

**SCHEDULE C**

**NOTICE OF INTENTION TO TRADE IN SECURITIES**

I hereby notify you of my intention to execute the following transaction in securities of Titan Medical Inc. ("Titan") and request approval of such transaction.

Type of transaction (check one):

- Purchase       Sale       Exercise of Stock Options       Other

If you selected "Other", please explain:

\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_

Number of Shares to be traded: \_\_\_\_\_

I confirm that I am aware of the legal prohibitions against insider trading and confirm that I am not in possession of any material information relating to Titan or any of its operations which has not been disclosed to the public generally.

I understand that Titan's *Insider Trading Policy* supplements, and does not replace, applicable insider trading laws. I understand that a violation of insider trading or tipping laws and regulations may subject me to severe civil and/or criminal penalties, and that violation of the terms of Titan's Insider Trading Policy will subject me to discipline by Titan, up to and including termination.

I understand that, notwithstanding any trading authorization granted upon approval of this form, I remain personally responsible for complying with the Insider Trading Policy and applicable laws and regulations.

I do hereby release Titan and each of its directors, officers, employees, agents and advisors from all claims and causes or rights of action that I may have against any of them in connection with the matters herein.

\_\_\_\_\_  
Name (*Please print*)

\_\_\_\_\_  
Signature

\_\_\_\_\_  
Date

\*\*\*\*\*

**AUTHORIZATION**

Authorized by: \_\_\_\_\_

Date: \_\_\_\_\_

Time: \_\_\_\_\_

This authorization is valid for five (5) business days, unless revoked prior to that time.